Abstract
BACKGROUND AND PURPOSE: Geometrical uncertainties in radiotherapy are generally accounted for by margins for tumors, but their effect on organs-at-risk (OARs) is often ignored. We developed a model that incorporates dose- and geometry-based uncertainties in OAR planning using dose constraints. MATERIALS AND METHODS: Radiotherapy uncertainties cause real dose-volume histograms (DVHs) to spread around the planned DVH. With a published OAR dose constraint D(V(crit)) < D(crit) such that complication probability < Y%, real differences from planned D(crit) can be described by mean- (MD(Dcrit)) and standard deviations (SD(Dcrit)). Assuming complications are associated with the worst DVHs, New dose constraints that maintain complication probability can be derived for new treatments: D(crit,New) = D(crit,publ) + Φ(-1)(1 - Y%) * (SD(Dcrit,publ) - SD(Dcrit,New)) + (MD(Dcrit,publ) - MD(Dcrit,New)), with Φ(-1)(x) the inverse cumulative normal distribution function. Setting SD(Dcrit,New) = MD(Dcrit,New) = 0 in the recipe yields the "True" critical dose, and D(crit,True) - D(crit,publ) can be considered a dose-based safety margin (DSM).As hypothetical example, we estimated MD(Dcrit) and SD(Dcrit) values by simulating geometric errors in our clinical treatment plans and adding dose-based uncertainty. Over 1000 OARs with 108 different regular- and hypo-fractionation constraints were simulated. We assumed accuracy SDs to change from 2.5mm/3% to 1.5mm/2%. RESULTS: Results varied per OAR, fractionation, and constraint-type. If our 2.5mm/3% MD(Dcrit) and SD(Dcrit) values approximated dose-constraint studies, on average the DSM would be 4.5 Gy (18%) and our dose constraints would increase with 1.2 Gy (5%). CONCLUSIONS: We introduced a first model relating dose constraints and complication probabilities with treatment uncertainties and safety margins for OARs. Among other things, it quantified how higher constraints can be applied with increasing radiotherapy accuracy.